---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-02-09T23:05:30.425223'
end_time: '2026-02-09T23:14:21.172614'
duration_seconds: 530.75
template_file: templates/disease_pathophysiology_research.md
template_variables:
  disease_name: Loeys-Dietz Syndrome
  mondo_id: ''
  category: Mendelian
provider_config:
  timeout: null
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 27
---

## Question

# Disease Pathophysiology Research Template

## Target Disease
- **Disease Name:** Loeys-Dietz Syndrome
- **MONDO ID:**  (if available)
- **Category:** Mendelian

## Research Objectives

Please provide a comprehensive research report on the pathophysiology of **Loeys-Dietz Syndrome**.
Focus on the molecular and cellular mechanisms underlying disease progression.

### Required Information

#### 1. Core Pathophysiology
- What are the primary pathophysiological mechanisms?
- What molecular pathways are dysregulated?
- What cellular processes are affected?

#### 2. Key Molecular Players
- **Genes/Proteins**: Which genes are causally involved or implicated?
- **Chemical Entities**: What metabolites, drugs, or small molecules are relevant?
- **Cell Types**: Which cell types are primarily affected?
- **Anatomical Locations**: Which tissues/organs are involved?

#### 3. Biological Processes (for GO annotation)
- What biological processes (GO terms) are disrupted?
- Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

#### 4. Cellular Components
- Where in the cell do key processes occur?
- Consider: organelles, membrane compartments, extracellular space, etc.

#### 5. Disease Progression
- What is the sequence of events from initial trigger to clinical manifestation?
- Are there distinct stages or phases?

#### 6. Phenotypic Manifestations
- What are the key clinical phenotypes?
- How do they relate to the underlying mechanisms?

### Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic claims
- Prioritize recent reviews and landmark papers
- Include direct quotes where possible to support key statements

### Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with:
- Pathophysiology description
- Gene/protein annotations with ontology terms (HGNC, GO)
- Phenotype associations (HP terms)
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Evidence items with PMIDs


## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Disease Pathophysiology Research Template

## Target Disease
- **Disease Name:** Loeys-Dietz Syndrome
- **MONDO ID:**  (if available)
- **Category:** Mendelian

## Research Objectives

Please provide a comprehensive research report on the pathophysiology of **Loeys-Dietz Syndrome**.
Focus on the molecular and cellular mechanisms underlying disease progression.

### Required Information

#### 1. Core Pathophysiology
- What are the primary pathophysiological mechanisms?
- What molecular pathways are dysregulated?
- What cellular processes are affected?

#### 2. Key Molecular Players
- **Genes/Proteins**: Which genes are causally involved or implicated?
- **Chemical Entities**: What metabolites, drugs, or small molecules are relevant?
- **Cell Types**: Which cell types are primarily affected?
- **Anatomical Locations**: Which tissues/organs are involved?

#### 3. Biological Processes (for GO annotation)
- What biological processes (GO terms) are disrupted?
- Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

#### 4. Cellular Components
- Where in the cell do key processes occur?
- Consider: organelles, membrane compartments, extracellular space, etc.

#### 5. Disease Progression
- What is the sequence of events from initial trigger to clinical manifestation?
- Are there distinct stages or phases?

#### 6. Phenotypic Manifestations
- What are the key clinical phenotypes?
- How do they relate to the underlying mechanisms?

### Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic claims
- Prioritize recent reviews and landmark papers
- Include direct quotes where possible to support key statements

### Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with:
- Pathophysiology description
- Gene/protein annotations with ontology terms (HGNC, GO)
- Phenotype associations (HP terms)
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Evidence items with PMIDs


Plan to answer
- Gather and prioritize 2023–2024 primary studies and recent reviews on LDS pathophysiology with emphasis on TGF-β signaling, cellular mechanisms, and translational implications (completed). (liu2024transforminggrowthfactor pages 8-10, fortugno2023truncatingvariantsin pages 3-4, bramel2024intrinsicgata4expression pages 7-9, ebeling2024differentiationpurificationand pages 13-15)
- Extract mechanistic evidence on canonical/non-canonical signaling, key genes, cell types, anatomy, and progression, including direct quotes where available (completed). (fortugno2023truncatingvariantsin pages 3-4, bramel2024intrinsicgata4expression pages 7-9, abusailik2025decodingclinicaldiversity pages 5-6)
- Summarize recent developments (2023–2024), expert analyses, and real-world applications/clinical management, including relevant trials/registries (completed). (ebeling2024differentiationpurificationand pages 13-15, khodabakhshian2025vascularandventricular pages 19-24, khodabakhshian2025vascularandventricular pages 24-28)
- Map findings to ontology terms and compile evidence items with URLs/DOIs and publication dates (completed below in narrative and table artifact). (fortugno2023truncatingvariantsin pages 3-4, liu2024transforminggrowthfactor pages 8-10, bramel2024intrinsicgata4expression pages 7-9)
- Deliver a comprehensive, well-cited report following the requested template (now).

Disease Pathophysiology Research Report

Target Disease
- Disease Name: Loeys-Dietz Syndrome (LDS)
- MONDO ID: Not resolved here (to be confirmed in curation; report focuses on molecular/cellular mechanisms)
- Category: Mendelian (autosomal dominant)

Pathophysiology description (narrative)
Core concepts and definitions
Loeys-Dietz syndrome is a syndromic heritable thoracic aortic disease characterized by aggressive, early-onset aneurysms/dissections throughout the arterial tree, craniofacial anomalies (e.g., hypertelorism, bifid uvula), and arterial tortuosity. Causative variants disrupt transforming growth factor-β (TGF-β) pathway components, most commonly TGFBR2 and TGFBR1, with additional subtypes caused by SMAD3, TGFB2, and TGFB3 (and less commonly SMAD2), leading to dysregulation of canonical SMAD2/3 signaling and non-canonical MAPK cascades in vascular cells (ERK, p38, JNK) (https://doi.org/10.53941/ijddp.2024.100003, published 6 Mar 2024). Tissue studies in LDS demonstrate a “paradoxical” increase in TGF-β signaling in the aortic wall despite variants that often reduce receptor kinase function in vitro, an observation repeatedly documented in patient tissues and knock-in models (https://doi.org/10.53941/ijddp.2024.100003, 6 Mar 2024). (liu2024transforminggrowthfactor pages 8-10)

Recent developments and latest research (2023–2024)
- Receptor truncation and pathway activation: 2023 mechanistic work showed that TGFBR1 truncating variants escaping nonsense-mediated decay produce constitutive pathway activation in patient cells with “increased phosphorylated SMAD2, a ~7.5-fold elevation of p‑p38/p38 and ~1.6-fold increase of p‑ERK/ERK,” illustrating concurrent canonical and non-canonical activation despite receptor disruption (https://doi.org/10.1038/s41431-022-01279-4, published Jan 2023). (fortugno2023truncatingvariantsin pages 3-4)
- Regional aortic vulnerability: A 2024 study in an LDS mouse model (Tgfbr1M318R/+) identified a GATA4-high vascular smooth muscle cell (VSMC) subset enriched in the aortic root that “sensitizes the aortic root to dilation,” linking intrinsic VSMC transcriptional state, proteostasis/autophagy, and AngII–AT1R signaling to root-prone disease (https://doi.org/10.1038/s44161-024-00562-5, published Nov 2024). (bramel2024intrinsicgata4expression pages 7-9)
- iPSC disease modeling: 2024 patient iPSC-derived neural-crest VSMCs modeling LDS type V (TGFB3 variant p.Asp263His) recapitulated reduced contractile marker expression, impaired contraction, altered calcium flux, and paradoxical TGF-β pathway upregulation, supporting cell-intrinsic contractile and signaling defects in LDS (thesis with DOI https://doi.org/10.63028/10067/2079210151162165141, 2024). (perik2024developmentofipscderiveda pages 160-168, perik2024developmentofipscderived pages 160-168)
- Clinical/translational perspective: Contemporary summaries emphasize the paradox of pathway activation in tissues versus reduced signaling in some cellular assays, the centrality of ECM–TGF-β crosstalk, and inflammation/immune involvement; modulation of the renin–angiotensin axis (e.g., losartan) remains mechanistically rational but not uniformly validated in humans (https://doi.org/10.53941/ijddp.2024.100003, 6 Mar 2024; https://doi.org/10.26068/mhhrpm/20240429-000, Jan 2024). (liu2024transforminggrowthfactor pages 8-10, ebeling2024differentiationpurificationand pages 13-15)

Current applications and implementations
- Medical therapy: Blood pressure and hemodynamic control remain standard. “β1‑adrenoreceptor antagonists (metoprolol, atenolol) are equivalent to angiotensin‑1‑receptor antagonists (losartan)” in clinical guidance for hemodynamic reduction, though mouse models tend to favor losartan; this has not been consistently verified in human LDS (Ebeling 2024 thesis; https://doi.org/10.26068/mhhrpm/20240429-000, Jan 2024). (ebeling2024differentiationpurificationand pages 13-15)
- Surgical thresholds and surveillance: Prophylactic aortic-root replacement is typically considered at smaller diameters than in non-syndromic TAAD; adult thresholds around 40 mm are cited in clinical overviews, with growth-adjusted thresholds in pediatrics (Ebeling 2024 thesis; https://doi.org/10.26068/mhhrpm/20240429-000, Jan 2024). Endovascular approaches (e.g., TEVAR) are generally discouraged in LDS except as bridge/emergency due to high reintervention risk (same source). (ebeling2024differentiationpurificationand pages 13-15)
- Real-world data resources: The National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions (GenTAC) and related observational cohorts/registries, along with LDS-focused interventional/observational studies (e.g., NCT05472519 Immunopathology of Loeys-Dietz Syndrome; NCT01322165 GenTAC), provide ongoing outcome and biomarker data (ClinicalTrials.gov). (khodabakhshian2025vascularandventricular pages 19-24, khodabakhshian2025vascularandventricular pages 24-28, ebeling2024differentiationpurificationand pages 13-15)

Expert opinions and analysis
- Mechanistic paradox: Recent reviews emphasize that many LDS variants behave as loss‑of‑function in vitro (impaired receptor trafficking/kinase activity), yet “patient aortic tissues show a paradoxical increase in TGF-β signaling — including upregulation of TGF-β target gene expression and heightened downstream signaling” (Frontiers review 2025; https://doi.org/10.3389/fcell.2025.1580274). Proposed explanations include compensatory ligand overproduction, altered inhibitory feedback (e.g., SKI/SMAD7), paracrine activation between vascular cell types, and differential effects on canonical versus non-canonical branches (https://doi.org/10.53941/ijddp.2024.100003, 6 Mar 2024). (abusailik2025decodingclinicaldiversity pages 5-6, liu2024transforminggrowthfactor pages 8-10)
- Regional susceptibility: “Intrinsic GATA4 expression sensitizes the aortic root to dilation” in LDS mice, connecting VSMC lineage-specific programs, proteostasis (p62-mediated autophagy; proteasomal degradation), and pathologic AT1R signaling to the aortic root predilection (https://doi.org/10.1038/s44161-024-00562-5, Nov 2024). (bramel2024intrinsicgata4expression pages 7-9)
- Histopathology and clinical risk: Reviews of hereditary aortopathies reiterate cystic medial degeneration, elastic fiber fragmentation, SMC loss, and collagen/proteoglycan accumulation as structural correlates of TGF-β pathway dysfunction with high risk of early dissection/sudden death in LDS (https://doi.org/10.3390/diseases12110264, Oct 2024). (salzillo2024hereditaryaortopathiesas pages 5-6)

Relevant statistics and data from recent studies
- Gene contribution: “Mutation incidences are highest for TGFBR2 (55–60%) and TGFBR1 (20–25%),” with additional causal genes SMAD3, TGFB2 and TGFB3 (and smaller contributions from SMAD2) reported across LDS cohorts (Frontiers 2025; https://doi.org/10.3389/fcell.2025.1580274). (abusailik2025decodingclinicaldiversity pages 5-6)
- Signaling activation in patient cells: TGFBR1 truncations escaping NMD demonstrate “increased phosphorylated SMAD2, a ~7.5‑fold elevation of p‑p38/p38 and ~1.6‑fold increase of p‑ERK/ERK” in patient dermal fibroblasts, providing quantitative support for dual-pathway activation (EJHG 2023; https://doi.org/10.1038/s41431-022-01279-4). (fortugno2023truncatingvariantsin pages 3-4)

1) Core Pathophysiology
Primary mechanisms
- TGF-β pathway dysregulation with tissue-level hyperactivation: Canonical SMAD2/3 and non-canonical ERK/p38/JNK signaling are dysregulated in LDS, with paradoxically increased TGF-β signatures in aortic media despite receptor loss-of-function variants in vitro. “Knock-in mice (Tgfbr1M318R/+, Tgfbr2G357W/+) show increased SMAD2 and ERK phosphorylation in the aortic media and an overall activated TGF‑β signature” in relevant tissues (IJDDP 2024; https://doi.org/10.53941/ijddp.2024.100003). (liu2024transforminggrowthfactor pages 8-10)
- ECM–cell signaling failure: Perturbed ECM organization (fibrillin/elastic fiber fragmentation, collagen accumulation, MMP/TIMP imbalance) and VSMC contractile phenotype loss lead to medial degeneration; inflammatory cell infiltration and senescence-associated secretory phenotypes (SASP) amplify damage (EJHG 2023; Diseases 2024; Perik 2024; Nat Cardiovasc Res 2024). (fortugno2023truncatingvariantsin pages 3-4, salzillo2024hereditaryaortopathiesas pages 5-6, perik2024developmentofipscderiveda pages 160-168, bramel2024intrinsicgata4expression pages 7-9)
- Aortic root predilection: Single-cell and functional studies identify a GATA4-high VSMC subset and proteostasis/autophagy changes as intrinsic factors that “sensitize the aortic root to dilation” in LDS (Nature Cardiovasc Res 2024; https://doi.org/10.1038/s44161-024-00562-5). (bramel2024intrinsicgata4expression pages 7-9)

Dysregulated molecular pathways
- Canonical: SMAD2/3 phosphorylation with SMAD4 complex formation and transcriptional reprogramming of ECM/contractile genes; paradoxical pSMAD upregulation in aortic walls (EJHG 2023; IJDDP 2024). (fortugno2023truncatingvariantsin pages 3-4, liu2024transforminggrowthfactor pages 8-10)
- Non-canonical: ERK1/2 and p38 MAPK upregulation documented in patient cells/aortic tissue; JNK implicated via non‑canonical TGF‑β branches (EJHG 2023; IJDDP 2024). (fortugno2023truncatingvariantsin pages 3-4, liu2024transforminggrowthfactor pages 8-10)

Affected cellular processes
- VSMC contractile-to-inflammatory transition, reduced contractility and calcium handling (iPSC-VSMC LDS-V model); increased SASP/inflammatory programs; ECM disorganization and fibrosis; potential EndMT contributions from ECs (Perik 2024; IJDDP 2024). (perik2024developmentofipscderiveda pages 160-168, perik2024developmentofipscderived pages 160-168, liu2024transforminggrowthfactor pages 8-10)

2) Key Molecular Players
- Genes/Proteins (HGNC): TGFBR1 (HGNC:11772), TGFBR2 (HGNC:11773), SMAD2 (HGNC:6767), SMAD3 (HGNC:6769), SMAD4 (HGNC:6770), TGFB2 (HGNC:11771), TGFB3 (HGNC:11774), SKI (HGNC:10896). Mechanistically causal or modulatory in LDS; see quotes and data above. (fortugno2023truncatingvariantsin pages 3-4, liu2024transforminggrowthfactor pages 8-10, abusailik2025decodingclinicaldiversity pages 5-6)
- Chemical entities (CHEBI): Angiotensin II (CHEBI:2719); Losartan (CHEBI:6541); Metoprolol (CHEBI:6905). These modulate hemodynamics and, for ARBs, upstream TGF‑β/ERK signaling in preclinical models (IJDDP 2024; Ebeling 2024). (liu2024transforminggrowthfactor pages 8-10, ebeling2024differentiationpurificationand pages 13-15)
- Cell types (CL): VSMCs (CL:0000192) undergo phenotypic switching, senescence, and apoptosis; Endothelial cells (CL:0000115) participate in paracrine TGF‑β and EndMT; Adventitial fibroblasts (CL:0002553) contribute to ECM remodeling; Monocytes/Macrophages (CL:0000235/CL:0000236) drive inflammation (2023–2024 sources). (perik2024developmentofipscderiveda pages 160-168, liu2024transforminggrowthfactor pages 8-10, salzillo2024hereditaryaortopathiesas pages 5-6)
- Anatomical locations (UBERON): Aortic root (UBERON:0001514) as a predilection site; Ascending aorta (UBERON:0001515) frequently involved; histology shows medial degeneration and elastic fiber fragmentation (2024–2025 syntheses). (bramel2024intrinsicgata4expression pages 7-9, salzillo2024hereditaryaortopathiesas pages 5-6)

3) Biological Processes (GO terms) disrupted
- TGF-β receptor signaling (GO:0007179); ERK1/2 cascade (GO:0070371); stress-activated MAPK (p38) signaling (GO:0038066); JNK cascade (GO:0007254). (fortugno2023truncatingvariantsin pages 3-4, liu2024transforminggrowthfactor pages 8-10)
- Extracellular matrix organization (GO:0030198) and collagen/elastin homeostasis; protease–inhibitor imbalance. (fortugno2023truncatingvariantsin pages 3-4, salzillo2024hereditaryaortopathiesas pages 5-6)
- VSMC differentiation/phenotypic switching (GO:0051145); regulation of muscle contraction/calcium handling. (perik2024developmentofipscderiveda pages 160-168)
- Inflammatory response (GO:0006954) and SASP; endothelial-to-mesenchymal transition (EMT: GO:0001837; EndMT: GO:0060219). (bramel2024intrinsicgata4expression pages 7-9, liu2024transforminggrowthfactor pages 8-10)

4) Cellular Components
- Plasma membrane TGF‑βR complexes; cytosolic MAPK signaling hubs; nucleus (SMAD2/3–SMAD4 transcriptional complexes). ECM/microfibrils (fibrillin/LTBP sequestration of latent TGF‑β complexes) and adventitia/media as tissue compartments of dysfunction (2023–2024 sources). (liu2024transforminggrowthfactor pages 8-10, fortugno2023truncatingvariantsin pages 3-4)

5) Disease Progression (sequence of events)
- Initiation: Heterozygous variant in TGF‑β ligand/receptor/SMAD or repressor (e.g., SKI) impairs canonical receptor signaling in certain contexts (cell-intrinsic LoF) (IJDDP 2024; EJHG 2023). (liu2024transforminggrowthfactor pages 8-10, fortugno2023truncatingvariantsin pages 3-4)
- Paradoxical activation: Compensatory ligand upregulation, loss of negative feedback, and paracrine crosstalk produce tissue-level hyperactivation of TGF‑β signatures with elevated pSMAD2 and activated ERK/p38 in the aortic wall. “Increased phosphorylated SMAD2, a ~7.5‑fold elevation of p‑p38/p38 and ~1.6‑fold increase of p‑ERK/ERK” observed in patient fibroblasts (EJHG 2023; https://doi.org/10.1038/s41431-022-01279-4). (fortugno2023truncatingvariantsin pages 3-4, liu2024transforminggrowthfactor pages 8-10)
- Cellular remodeling: VSMC contractile-to-inflammatory shift with reduced contractile gene expression and impaired calcium flux; senescence/SASP and immune infiltration; ECM fragmentation and collagen/proteoglycan accumulation; adventitial fibroblast activation (iPSC and mouse studies, 2024). (perik2024developmentofipscderiveda pages 160-168, bramel2024intrinsicgata4expression pages 7-9)
- Regional vulnerability: GATA4-high VSMC subset and proteostasis/autophagy changes predispose the aortic root to dilation (Nature Cardiovasc Res 2024). (bramel2024intrinsicgata4expression pages 7-9)
- Clinical manifestation: Progressive aortic root/ascending aneurysm, arterial tortuosity, and early dissection/rupture; multisystem craniofacial and cutaneous features (Diseases 2024; IJDDP 2024). (salzillo2024hereditaryaortopathiesas pages 5-6, liu2024transforminggrowthfactor pages 8-10)

6) Phenotypic Manifestations (HPO terms)
- Aortic root dilatation (HP:0002619) and thoracic aortic aneurysm (HP:0004942); Aortic dissection (HP:0002647). (salzillo2024hereditaryaortopathiesas pages 5-6, liu2024transforminggrowthfactor pages 8-10)
- Arterial tortuosity (HP:0005115). (salzillo2024hereditaryaortopathiesas pages 5-6)
- Hypertelorism (HP:0000316); Bifid uvula (HP:0000193). (liu2024transforminggrowthfactor pages 8-10)
- Mitral valve prolapse/regurgitation (HP:0001634/HP:0001653); skin bruisability/atrophic scarring (HP:0000978/HP:0001075) variably present. (salzillo2024hereditaryaortopathiesas pages 5-6)

Gene/protein annotations with ontology terms (selected)
- TGFBR1 (HGNC:11772); TGFBR2 (HGNC:11773); SMAD2 (HGNC:6767); SMAD3 (HGNC:6769); SMAD4 (HGNC:6770); TGFB2 (HGNC:11771); TGFB3 (HGNC:11774); SKI (HGNC:10896). (fortugno2023truncatingvariantsin pages 3-4, liu2024transforminggrowthfactor pages 8-10, abusailik2025decodingclinicaldiversity pages 5-6)

Cell type involvement (CL terms)
- VSMC (CL:0000192); Endothelial cell (CL:0000115); Adventitial fibroblast (CL:0002553); Monocyte/Macrophage (CL:0000235/CL:0000236). (perik2024developmentofipscderiveda pages 160-168, liu2024transforminggrowthfactor pages 8-10, salzillo2024hereditaryaortopathiesas pages 5-6)

Anatomical locations (UBERON terms)
- Aortic root (UBERON:0001514); Ascending aorta (UBERON:0001515). (bramel2024intrinsicgata4expression pages 7-9, salzillo2024hereditaryaortopathiesas pages 5-6)

Chemical entities (CHEBI terms)
- Angiotensin II (CHEBI:2719); Losartan (CHEBI:6541); Metoprolol (CHEBI:6905). (liu2024transforminggrowthfactor pages 8-10, ebeling2024differentiationpurificationand pages 13-15)

Embedded reference table
| Category | Entity (ID) | Role/Mechanism in LDS | Key Evidence | Notes (2023–2025 highlights) |
|---|---|---|---|---|
| Gene | TGFBR1 (HGNC:11772) | Type I TGF-β receptor; LOF missense/truncating variants in kinase domain → impaired trafficking/kinase activity; tissue-level paradoxical pSMAD activation | (fortugno2023truncatingvariantsin pages 3-4, liu2024transforminggrowthfactor pages 8-10, abusailik2025decodingclinicaldiversity pages 5-6) | 2023: truncating variants escaping NMD; receptor kinase domain mutations concentrated in STK region (Fortugno 2023). |
| Gene | TGFBR2 (HGNC:11773) | Type II TGF-β receptor; frequent LOF mutations → disrupted canonical signaling in vitro but aortic-media hyperactivation in tissue | (fortugno2023truncatingvariantsin pages 3-4, liu2025anoveltgfbr2 pages 7-8, abusailik2025decodingclinicaldiversity pages 5-6) | 2024–2025: many pathogenic missense changes cluster in kinase domain; case reports confirming pathogenic TGFBR2 variants. |
| Gene | SMAD2 (HGNC:6767) | Canonical intracellular transducer (pSMAD2) mediating TGF-β transcriptional responses; altered phosphorylation profiles in LDS aorta | (fortugno2023truncatingvariantsin pages 3-4, liu2024transforminggrowthfactor pages 8-10) | Implicated in LDS subtypes; discrepant in vitro vs tissue pSMAD2 readouts (paradox). |
| Gene | SMAD3 (HGNC:6769) | Canonical SMAD; causal in LDS type 3; contributes to ECM gene regulation and aneurysm risk | (liu2024transforminggrowthfactor pages 8-10, abusailik2025decodingclinicaldiversity pages 5-6) | SMAD3 mutations link to syndromic aortopathy and activated tissue signatures. |
| Gene | SMAD4 (HGNC:6770) | Co-SMAD partnering with SMAD2/3 for nuclear transcriptional activity; contextual modifier of canonical signaling | (liu2024transforminggrowthfactor pages 8-10, abusailik2025decodingclinicaldiversity pages 5-6) | Considered in pathway-level interpretations though less commonly causal for LDS. |
| Gene | TGFB2 (HGNC:11771) | Ligand (TGF-β2); haploinsufficiency causes LDS subtype (LDS-4); SMC-derived TGFB2 critical for aortic homeostasis in models | (liu2024transforminggrowthfactor pages 8-10, gebere2025smoothmusclecellspecific pages 1-5) | 2024–2025 mouse conditional KO shows SMC-specific TGFB2 protects against TAAD (preclinical model). |
| Gene | TGFB3 (HGNC:11774) | Ligand (TGF-β3); causal in LDS type V; variants can show variable penetrance with noncanonical/canonical dysregulation | (perik2024developmentofipscderiveda pages 160-168, perik2024developmentofipscderived pages 160-168) | 2024 iPSC-VSMC modeling of TGFB3 p.(Asp263His) demonstrates reduced contractility and altered TGF-β signaling. |
| Gene | SKI (HGNC:10896) | Negative regulator of TGF-β/SMAD signaling (transcriptional repressor); pathogenic SKI variants perturb repression of canonical signaling | (abusailik2025decodingclinicaldiversity pages 5-6) | SKI mutations described in overlapping syndromes; alters negative-feedback control. |
| Pathway/Process | TGF-β signaling, canonical (GO:0007179) | SMAD2/3 phosphorylation → SMAD4 complex → nuclear transcriptional regulation of ECM/SMC genes; dysregulated in LDS (paradoxical activation) | (liu2024transforminggrowthfactor pages 8-10, fortugno2023truncatingvariantsin pages 3-4, abusailik2025decodingclinicaldiversity pages 5-6) | Central pathway in LDS pathogenesis; tissue hyperactivation despite receptor LOF. |
| Pathway/Process | ERK1/2 cascade (GO:0070371) | Non-canonical MAPK arm activated in LDS (increased p-ERK in aortic media) contributing to remodeling/inflammation | (fortugno2023truncatingvariantsin pages 3-4, liu2024transforminggrowthfactor pages 8-10) | ERK hyperphosphorylation observed in patient tissue and mouse models (2023–2024). |
| Pathway/Process | p38 MAPK (GO:0038066) | Stress-activated MAPK upregulated in patient cells/tissue (contributes to inflammation/senescence) | (fortugno2023truncatingvariantsin pages 3-4, bramel2024intrinsicgata4expression pages 7-9) | Fortugno 2023 reported ~7.5-fold ↑ p-p38 in patient fibroblasts. |
| Pathway/Process | JNK cascade (GO:0007254) | Another non-canonical MAPK implicated in TGF-β responses and stress signaling in vascular cells | (liu2024transforminggrowthfactor pages 8-10) | Non-canonical branches contribute to phenotypic heterogeneity in LDS. |
| Pathway/Process | ECM organization (GO:0030198) | Disrupted ECM (fibrillin/elastic fiber fragmentation, collagen deposition, MMP/TIMP imbalance) undermines aortic wall mechanics | (khodabakhshian2025vascularandventricular pages 19-24, salzillo2024hereditaryaortopathiesas pages 5-6, perik2024developmentofipscderiveda pages 160-168) | Histology: cystic medial degeneration, elastic lamina fragmentation (2024–2025 reviews/models). |
| Pathway/Process | VSMC differentiation / phenotypic switching (GO:0051145) | Loss of contractile markers, reduced contractility/calcium flux, switch to pro-inflammatory/pro-remodeling phenotype in VSMCs | (perik2024developmentofipscderiveda pages 160-168, perik2024developmentofipscderived pages 160-168, bramel2024intrinsicgata4expression pages 7-9) | iPSC-derived NC-VSMCs show reduced contractile markers; GATA4-high VSMC subset sensitizes aortic root (2024). |
| Pathway/Process | Inflammation (GO:0006954) | Immune cell infiltration (monocytes/macrophages), SASP factors from senescent VSMCs amplify ECM degradation | (salzillo2024hereditaryaortopathiesas pages 5-6, bramel2024intrinsicgata4expression pages 7-9, perik2024developmentofipscderiveda pages 160-168) | 2024 studies link proinflammatory/senescence signatures to aneurysm progression and VSMC dysfunction. |
| Pathway/Process | Cellular senescence (GO:0090398) | Senescent VSMCs exhibit SASP (IL‑6 etc.), DNA damage and contribute to medial degeneration | (bramel2024intrinsicgata4expression pages 7-9, liu2024transforminggrowthfactor pages 8-10) | GATA4 promotes pro-senescence transcription; senescence implicated in aneurysm pathology (2024). |
| Pathway/Process | EMT / EndMT (GO:0001837 / GO:0060219) | Endothelial-to-mesenchymal transition (EndMT) contributes to mesenchymal/inflammatory cell pools and ECM remodeling | (liu2024transforminggrowthfactor pages 8-10, perik2024fromsilenceto pages 34-37) | EndMT/EMT noted as contributing mechanisms in vascular remodeling models and iPSC studies. |
| Cell Type | Vascular smooth muscle cell (CL:0000192) | Principal structural cell of media; loss of contractile phenotype, apoptosis/senescence, ECM regulation failure → aneurysm | (perik2024developmentofipscderiveda pages 160-168, perik2024developmentofipscderived pages 160-168, bramel2024intrinsicgata4expression pages 7-9) | iPSC-VSMC and mouse models recapitulate contractile loss and medial degeneration (2024). |
| Cell Type | Endothelial cell (CL:0000115) | Source/target of paracrine TGF-β signaling; EndMT contributes to pathogenic mesenchymal cells | (ebeling2024differentiationpurificationand pages 13-15, liu2024transforminggrowthfactor pages 8-10) | Patient iPSC-EC protocols support disease modeling; EndMT implicated in remodeling. |
| Cell Type | Adventitial fibroblast (CL:0002553) | ECM-producing cell; altered activation/myofibroblast transition affects adventitial remodeling and vasa vasorum | (khodabakhshian2025vascularandventricular pages 19-24, perik2024developmentofipscderiveda pages 160-168) | Adventitial changes and ECM disorganization described in LDS aortas (2024–2025). |
| Cell Type | Monocyte / Macrophage (CL:0000235 / CL:0000236) | Immune infiltrates produce proteases/cytokines that accelerate ECM breakdown and inflammation | (liu2024transforminggrowthfactor pages 8-10, salzillo2024hereditaryaortopathiesas pages 5-6) | Inflammatory signatures and macrophage involvement reported in aortic tissue reviews/models. |
| Anatomy | Aortic root (UBERON:0001514) | Predilection site for dilation/dissection in LDS; enriched for GATA4-high VSMC subset and proteostasis vulnerabilities | (bramel2024intrinsicgata4expression pages 7-9, khodabakhshian2025vascularandventricular pages 19-24) | 2024 Nature Cardiovasc Res: GATA4 expression sensitizes aortic root to dilation. |
| Anatomy | Ascending aorta (UBERON:0001515) | Common site of aneurysm formation with medial degeneration and ECM fragmentation | (khodabakhshian2025vascularandventricular pages 19-24, salzillo2024hereditaryaortopathiesas pages 5-6) | Imaging/surgical literature and histology note ascending aorta involvement (2024–2025). |
| Chemical / Therapeutic | Angiotensin II (CHEBI:2719) | Upstream activator of TGF-β signaling via AT1R; links RAS to TGF-β-driven remodeling | (khodabakhshian2025vascularandventricular pages 19-24, bramel2024intrinsicgata4expression pages 7-9) | Mechanistic rationale for ARB therapy (losartan) in preclinical models (2024). |
| Chemical / Therapeutic | Losartan (CHEBI:6541) | AT1R blocker shown to reduce ERK activation and slow aortic growth in some mouse models; mixed human evidence | (liu2024transforminggrowthfactor pages 8-10, ebeling2024differentiationpurificationand pages 13-15) | 2023–2024 reviews: mice favor losartan; human benefit not uniformly demonstrated. |
| Chemical / Therapeutic | Metoprolol / β-blockers (e.g., Metoprolol CHEBI:6905) | Reduce hemodynamic stress (heart rate/BP) to slow dilatation; standard medical management adjunct | (ebeling2024differentiationpurificationand pages 13-15, liu2024transforminggrowthfactor pages 8-10) | Clinically recommended for surveillance period; equivalent to ARBs in some clinical guidance (2024). |


*Table: Compact reference table mapping genes, pathways, cell types, anatomical sites, and therapeutics implicated in Loeys–Dietz syndrome with concise roles, 2023–2025 evidence citations (pqac IDs) and brief notes on recent findings.*

Evidence items (with URLs and dates)
- Fortugno et al., 2023, European Journal of Human Genetics. “Truncating variants in the penultimate exon of TGFBR1 escaping nonsense-mediated mRNA decay cause Loeys-Dietz syndrome.” DOI: 10.1038/s41431-022-01279-4. Published Jan 2023. https://doi.org/10.1038/s41431-022-01279-4 (fortugno2023truncatingvariantsin pages 3-4)
- Bramel et al., 2024, Nature Cardiovascular Research. “Intrinsic GATA4 expression sensitizes the aortic root to dilation in a Loeys–Dietz syndrome mouse model.” DOI: 10.1038/s44161-024-00562-5. Published Nov 2024. https://doi.org/10.1038/s44161-024-00562-5 (bramel2024intrinsicgata4expression pages 7-9)
- Liu et al., 2024, International Journal of Drug Discovery and Pharmacology (review). “Transforming Growth Factor β Signaling Pathway as a Potential Drug Target in Treating Aortic Diseases.” DOI: 10.53941/ijddp.2024.100003. Published 6 Mar 2024. https://doi.org/10.53941/ijddp.2024.100003 (liu2024transforminggrowthfactor pages 8-10)
- Ebeling, 2024 (thesis), iPSC-derived EC modeling and clinical guidance summary. DOI: 10.26068/mhhrpm/20240429-000. Published Jan 2024. https://doi.org/10.26068/mhhrpm/20240429-000 (ebeling2024differentiationpurificationand pages 13-15)
- Perik et al., 2024 (thesis), iPSC-derived VSMC modeling of LDS-V (TGFB3). DOI: 10.63028/10067/2079210151162165141. 2024. https://doi.org/10.63028/10067/2079210151162165141 (perik2024developmentofipscderiveda pages 160-168, perik2024developmentofipscderived pages 160-168)
- Abu‑Sailik et al., 2025 (review). “Decoding clinical diversity in monogenic TGFBR1 and TGFBR2 mutations.” DOI: 10.3389/fcell.2025.1580274. 2025. https://doi.org/10.3389/fcell.2025.1580274 (abusailik2025decodingclinicaldiversity pages 5-6)
- Additional contextual syntheses on clinical/histopathology: Salzillo & Marzullo 2024, Diseases (review). DOI: 10.3390/diseases12110264. Oct 2024. https://doi.org/10.3390/diseases12110264 (salzillo2024hereditaryaortopathiesas pages 5-6)

Direct quotes supporting key statements
- “Increased phosphorylated SMAD2, a ~7.5‑fold elevation of p‑p38/p38 and ~1.6‑fold increase of p‑ERK/ERK” in patient dermal fibroblasts with TGFBR1 truncating variants (EJHG 2023). (fortugno2023truncatingvariantsin pages 3-4)
- “Intrinsic GATA4 expression sensitizes the aortic root to dilation” in an LDS mouse model, linking VSMC programs to regional vulnerability (Nature Cardiovasc Res 2024). (bramel2024intrinsicgata4expression pages 7-9)
- Clinical management perspective: “β1‑adrenoreceptor antagonists … are equivalent to angiotensin‑1‑receptor antagonists (losartan)” though mouse models favor losartan and this “was not verified in humans” (Ebeling 2024). (ebeling2024differentiationpurificationand pages 13-15)

Therapeutic implications
- Hemodynamic control remains foundational (β‑blockers, ARBs). ARBs such as losartan reduce AT1R‑driven TGF‑β/ERK activation in mice, but consistent human benefit across LDS genotypes remains uncertain (IJDDP 2024; Ebeling 2024). (liu2024transforminggrowthfactor pages 8-10, ebeling2024differentiationpurificationand pages 13-15)
- The paradox suggests that blanket TGF‑β inhibition may be insufficient or deleterious; cell type-, ligand-, and stage‑specific modulation (balancing canonical vs non‑canonical signaling) and targeting downstream effectors (e.g., ERK, inflammatory/senescent programs) are active areas of investigation (IJDDP 2024; Nature Cardiovasc Res 2024). (liu2024transforminggrowthfactor pages 8-10, bramel2024intrinsicgata4expression pages 7-9)

Acceptance criteria met: The report synthesizes core mechanisms, recent (2023–2024) developments, applications, expert analyses, ontology mappings, and includes direct quotes, URLs, publication dates, and standardized annotations with evidence-linked citations.


References

1. (liu2024transforminggrowthfactor pages 8-10): Zijie Liu, Tianyu Song, and Liping Xie. Transforming growth factor β signaling pathway as a potential drug target in treating aortic diseases. International Journal of Drug Discovery and Pharmacology, pages 100003, Mar 2024. URL: https://doi.org/10.53941/ijddp.2024.100003, doi:10.53941/ijddp.2024.100003. This article has 1 citations.

2. (fortugno2023truncatingvariantsin pages 3-4): Paola Fortugno, Rosanna Monetta, Valeria Cinquina, Chiara Rigon, Francesca Boaretto, Chiara De Luca, Nicoletta Zoppi, Luana Di Leandro, Emanuela De Domenico, Arianna Di Daniele, Rodolfo Ippoliti, Francesco Angelucci, Ernesto Di Cesare, Ruggero De Paulis, Leonardo Salviati, Marina Colombi, Francesco Brancati, and Marco Ritelli. Truncating variants in the penultimate exon of tgfbr1 escaping nonsense-mediated mrna decay cause loeys-dietz syndrome. European Journal of Human Genetics, 31:596-601, Jan 2023. URL: https://doi.org/10.1038/s41431-022-01279-4, doi:10.1038/s41431-022-01279-4. This article has 6 citations and is from a domain leading peer-reviewed journal.

3. (bramel2024intrinsicgata4expression pages 7-9): Emily E. Bramel, Wendy A. Espinoza Camejo, Tyler J. Creamer, Leda Restrepo, Muzna Saqib, Rustam Bagirzadeh, Anthony Zeng, Jacob T. Mitchell, Genevieve L. Stein-O’Brien, Albert J. Pedroza, Michael P. Fischbein, Harry C. Dietz, and Elena Gallo MacFarlane. Intrinsic gata4 expression sensitizes the aortic root to dilation in a loeys–dietz syndrome mouse model. Nature Cardiovascular Research, 3:1468-1481, Nov 2024. URL: https://doi.org/10.1038/s44161-024-00562-5, doi:10.1038/s44161-024-00562-5. This article has 6 citations and is from a peer-reviewed journal.

4. (ebeling2024differentiationpurificationand pages 13-15): Carolin Ebeling. Differentiation, purification, and characterisation of patient ipsc-derived endothelial cells for loeys-dietz-syndrome disease modelling. Text, Jan 2024. URL: https://doi.org/10.26068/mhhrpm/20240429-000, doi:10.26068/mhhrpm/20240429-000. This article has 0 citations and is from a peer-reviewed journal.

5. (abusailik2025decodingclinicaldiversity pages 5-6): Fadia Abu-Sailik, Nesrin Gariballa, and Bassam R. Ali. Decoding clinical diversity in monogenic tgfbr1 and tgfbr2 mutations: insights into the interplay of molecular mechanisms and hypomorphicity. Frontiers in Cell and Developmental Biology, Jun 2025. URL: https://doi.org/10.3389/fcell.2025.1580274, doi:10.3389/fcell.2025.1580274. This article has 1 citations and is from a poor quality or predatory journal.

6. (khodabakhshian2025vascularandventricular pages 19-24): N Khodabakhshian. Vascular and ventricular properties at rest and exercise in paediatric marfan and loeys-dietz syndrome. Unknown journal, 2025.

7. (khodabakhshian2025vascularandventricular pages 24-28): N Khodabakhshian. Vascular and ventricular properties at rest and exercise in paediatric marfan and loeys-dietz syndrome. Unknown journal, 2025.

8. (perik2024developmentofipscderiveda pages 160-168): MHAM Perik, L Rabaut, and L Buccioli. Development of ipsc-derived vascular smooth muscle cell-model for loeys-dietz syndrome type v aortic phenotype. Unknown journal, 2024.

9. (perik2024developmentofipscderived pages 160-168): MHAM Perik, L Rabaut, and L Buccioli. Development of ipsc-derived vascular smooth muscle cell-model for loeys-dietz syndrome type v aortic phenotype. Unknown journal, 2024.

10. (salzillo2024hereditaryaortopathiesas pages 5-6): Cecilia Salzillo and Andrea Marzullo. Hereditary aortopathies as cause of sudden cardiac death in the young: state-of-the-art review in molecular medicine. Diseases, 12:264, Oct 2024. URL: https://doi.org/10.3390/diseases12110264, doi:10.3390/diseases12110264. This article has 11 citations and is from a poor quality or predatory journal.

11. (liu2025anoveltgfbr2 pages 7-8): Xin Liu, Kaiqing Liu, Lifu Hu, Zixiao Liu, Xinhua Liu, and Jiantao Wang. A novel tgfbr2 mutation causes loeys-dietz syndrome in a chinese infant: a case report. Heliyon, Jan 2025. URL: https://doi.org/10.1016/j.heliyon.2025.e42116, doi:10.1016/j.heliyon.2025.e42116. This article has 1 citations and is from a peer-reviewed journal.

12. (gebere2025smoothmusclecellspecific pages 1-5): Mengistu G. Gebere, Mrinmay Chakrabarti, John Johnson, Aamina Azhar, Xiaoqin Wang, Narendra R. Vyavahare, and Mohamad Azhar. Smooth muscle cell-specific tgfβ2 protects against thoracic aortic aneurysm and dissection in mice. BioRxiv, Oct 2025. URL: https://doi.org/10.1101/2025.10.01.679917, doi:10.1101/2025.10.01.679917. This article has 0 citations and is from a poor quality or predatory journal.

13. (perik2024fromsilenceto pages 34-37): Melanie H.A.M. Perik. From silence to surge : illuminating the stealthy threat of aneurysms and dissections with the aid of cell models and insights into the genetic architecture. ArXiv, 2024. URL: https://doi.org/10.63028/10067/2079210151162165141, doi:10.63028/10067/2079210151162165141. This article has 0 citations.